Blazing a New Trail

Trishula Therapeutics is dedicated to improving outcomes for people with cancer by developing TTX-030, a first-in-class, anti-CD39 antibody.

About Us

Our Science

Our focus is on developing transformational cancer medicines by targeting the mechanisms of immune evasion in the tumor microenvironment. TTX-030, a novel, first-in-class antibody, is currently being studied in phase 1/1b clinical trials.

Learn More